UOX and hyperuricemia: Therapeutic effects of urate oxidase by intravenous administration was reported by London and Hudson in 1957 and Rasburicase, a recombinant urate oxidase, was approved after 44 years for treating severe hyperuricemia in patients receiving chemotherapy in Europe and US (Kennedy and Ajiboye 2010).